ArticleAnnals of internal medicine2021

In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.

Michael TannerPubMed ↗Publisher ↗

No numbers read from the abstract.